Aleksandra Blagojevic graduated from the University of Basel with a Master in Drug Sciences in April 2021.

Before starting her master thesis, she worked in the Global Technical Development of Synthetic Molecules at Roche as an intern in the division of Services & Systems.

Later she conducted her master thesis “Developing and analysing novel complement pathway inhibitors by mimicking a parasitic protein” in the Molecular Pharmacy group at the University of Basel, under the supervision of Prof. Dr. Daniel Ricklin.

In June 2021 she joined the Molecular Pharmacy research group as PhD student. Her research focuses on the analysis of parasitic immune evasion proteins and components of the complement system. The aim is to develop novel inhibitors for therapeutic regulation of the complement initiation pathways.